Richard A. Heyman has an estimated net worth of $31.4 Million. This is based on reported shares across multiple companies, which include Enliven Therapeutics, Inc., Receptos, Inc., PMV Pharmaceuticals, Inc., Gritstone bio, Inc., BCTG Acquisition Corp., ORGANOVO HOLDINGS, INC., Metacrine, Inc., Oric Pharmaceuticals, Inc., YUMANITY THERAPEUTICS, INC., and RayzeBio, Inc..

2021 was Richard A. Heyman's most active year for acquiring shares with 10 total transactions. Richard A. Heyman's most active month to acquire stocks was the month of May. 2021 was Richard A. Heyman's most active year for disposing of shares, totalling 27 transactions. Richard A. Heyman's most active month to dispose stocks was the month of May. 2021 saw Richard A. Heyman paying a total of $959,253.75 for 94,898 shares, this is the most they've acquired in one year. In 2024 Richard A. Heyman cashed out on 393,104 shares for a total of $23,580,424.73, their largest year based on trade value.